Development of Easywire Supported by Board of Leading Experts
QUEBEC CITY, Dec. 20 /CNW Telbec/ - Opsens Inc. (TSX VENTURE EXCHANGE:
OPS) ("Opsens") today unveiled the EasyWire, developed by its medical
division for the growth market of Fractional Flow Reserve for coronary
Fractional Flow Reserve (FFR) is an index of the functional severity of
a coronary stenosis that is calculated from pressure measurements taken
before and after a narrowing of the arteries during coronary
arteriography. This increasingly used approach enables an "on the spot"
diagnosis for a better assessment as to whether a stent is an
appropriate intervention to improve blood circulation in the
A 2009 study, "Fractional Flow Reserve vs. Angiography for Multivessel
Evaluation", published in the New England Journal of Medicine, found
that a stent was not always an appropriate intervention, and its
overuse was actually doing patients more harm than good in some cases.
Patients of doctors using FFR had fewer stents used and better outcomes
overall, the study found.
"The FAME study has been influential in the adoption of FFR as a
technique for assessing patients," said Claude Belleville, VP Medical
of Opsens. "The FFR market, while in its early stages, has been growing
exponentially as doctors understand the potential for improved patient
"The FFR market represents a real and significant opportunity for Opsens
and its shareholders," said Pierre Carrier, Opsens President and CEO.
"We intend to fully exploit this opportunity through the aggressive
development of EasyWire through the stages of animal and human testing,
and then commercialization."
Scientific Advisory Board
To support the development and refinement of EasyWire, Opsens is
supported by a team of experts in the field of FFR and clinical
research to form a scientific advisory board, composed of Drs. Morton
Kern, Olivier F. Bertrand and Michael J. Lim. These leading
cardiologists are advising the Company on the development, clinical
studies and commercialization of EasyWire.
Dr. Kern, of Orange, California, is an interventional cardiology and internal
medicine specialist focused more precisely on heart and cardiovascular
diseases, and is respected as one of the most foremost experts on FFR
in the world. His clinical interests lean towards coronary
angioplasties and stenting, physiology and intravascular sonograms, and
cardiovascular hemodynamic. He has authored several major textbooks,
one of which is the leading book on cardiac catheterization, entitled
"The Cardiac Catheterization Handbook", which is used internationally
to train physicians.
Dr. Bertrand, of Quebec City, Quebec, is an interventional cardiologist and
researcher with the Quebec Heart-Lung Institute, affiliated to Laval
University. He is active in clinical research, particularly in the
field of intervention and treatment of coronary cardiac diseases. He
acts as principal investigator of clinical trials and is also the
initiator of several original projects of clinical research
(investigator-initiated trials) on a worldwide scale. He has a PhD in
experimental medicine from McGill University in Montreal, among his
educational achievements. Dr. Bertrand is widely published, counting
125 articles and 13 book chapters to his credit.
Dr. Lim, of St. Louis, Missouri, is the acting director of the Cardiology
Division at Saint Louis University, where he also serves as the
director of the Cardiac Catheterization Laboratory. He is also the
co-chairman of the acute myocardial infarction treatment improvement
team, and the Saint Louis University Hospital EMS advisory board. He
currently performs diagnostic and percutaneous coronary and vascular
interventions in the J. Gerard Mudd Cardiac Catheterization Laboratory
at Saint Louis University Hospital. His research interests include
acute coronary syndromes and interventional physiologic coronary
Opsens director Steven Arless will work together with the advisory board. Mr. Arless has over 35 years of international marketing and sales
experience in the medical devices and pharmaceutical industries,
including 17 years at Smith & Nephew Inc., and 10 years as President
and CEO of CryoCath Technologies Inc. He is currently CEO of
CardioInsight Technologies Inc., a Cleveland-based company developing
and commercializing cardiovascular technology.
EasyWire for the Measurement of Fractional Flow Reserve
Opsens' product, EasyWire, is a miniature catheter that slides over a
vast variety of guide wires. EasyWire provides a no-drift, highly
accurate and reliable measurement of blood pressure in coronary
arteries and gives cardiologists the freedom to use their favourite
guide wire. With EasyWire the cardiologist can reach the area under
investigation faster and easier than with other products on the market,
simplifying the procedure.
"In the same way that an artist has preferred brushes, cardiologists
have guide wires that have the right feel for them. Unlike other FFR
devices on the market, EasyWire concept allows doctors to use their
preferred guide wire, at the same time giving them the benefit of
having optical pressure sensing," said Dr. Bertrand.
Opsens has filed a patent application for the EasyWire, "Eccentric
Pressure Catheter with Guidewire Capability". A US patent for the fiber
optic pressure sensor used within the EasyWire was also recently
granted to Opsens. The monitoring technology used in the EasyWire is
based on the same patented White-Light Polarization Interferometry
technology used in Opsens' oil and gas OPP-W systems. The company is
developing both arms of the business in parallel, exploiting potential
in both markets for its unique fiber optic sensing technology.
About Opsens (www.opsens.com)
Opsens is a leading developer, manufacturer and supplier of a wide range
of fiber optic sensors and associated signal conditioners based on
proprietary patented and patent pending technologies. Opsens' sensors
provide long-term accuracy and reliability in the harshest
environments. Opsens provides sensors to measure pressure, temperature,
strain and displacement to original equipment manufacturers (OEM) and
end-users in the oil and gas, medical and laboratory fields. Opsens
provides complete technical support, including installation, training,
after-sales service, for its fiber optics systems that are regulated by
the ISO 9001-2008 norm.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements contained in this press release involve known
and unknown risks, uncertainties and other factors that may cause
actual results, performance and achievements of Opsens to be materially
different from any future results, performance or achievements
expressed or implied by the said forward-looking statements.
Opsens Inc was recognized as a TSX Venture 50® company in 2010. TSX
Venture 50 is a trade-mark of TSX Inc. and is used under license.
SOURCE Opsens Inc.
For further information: For further information:
|Pierre Carrier || || || || ||Louis Laflamme, CA || |
|President and Chief Executive Officer || || || || ||Chief Financial Officer || |
|Tel: 418.682.9996 || || || || ||Tel: 418.682.9996|